Enzymatica AB (publ)

Stockholm Stock Exchange ENZY.ST

Enzymatica AB (publ) Shareholders' Equity for the year ending December 31, 2023: USD 7.56 M

Enzymatica AB (publ) Shareholders' Equity is USD 7.56 M for the year ending December 31, 2023, a -37.31% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Enzymatica AB (publ) Shareholders' Equity for the year ending December 31, 2022 was USD 12.06 M, a -12.34% change year over year.
Enzymatica AB (publ) Shareholders' Equity for the year ending December 31, 2021 was USD 13.76 M, a 6.45% change year over year.
Enzymatica AB (publ) Shareholders' Equity for the year ending December 31, 2020 was USD 12.93 M, a 1.91% change year over year.
Enzymatica AB (publ) Shareholders' Equity for the year ending December 31, 2019 was USD 12.68 M, a -29.39% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Stockholm Stock Exchange: ENZY.ST

Enzymatica AB (publ)

CEO	Mr. Claus Egstrand
IPO Date	June 14, 2011
Location	Sweden
Headquarters	Ideon Science Park
Employees	17
Sector	Healthcare
Industries Biotechnology Cleaning Supplies Dental Care Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics Vaccines

Description

Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme mouth spray, which prevents common cold and reduces the duration of illness. It also provides enzyme formulations. The company sells mouth spray under the ViruProtect brand in Denmark; STADAProtect brand in Germany; Psysiomer Stop Virus brand in France; and Zerinol Virus Defense brand in Italy. Enzymatica AB was incorporated in 2007 and is headquartered in Lund, Sweden.

Key trends

Past 5 years